kısım 1 temel kalp yetersizliği - Rasim Enar

Kalp Yetersizliği Sendromu 137
assessing the effect of digoxin withdrawal in patients with
mild to moderate chronic congestive heart failure: results of
the PROVED trial. PROVED Investigative Group. /. Am. Coll.
Cardiol. 1993;22(4):955-962.
Quinapril Heart Failure Trial.
Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical
consequences of angiotensin-converting enzyme inhibitor
withdrawal in chronic heart failure: a double-blind, placebo-controlled
study of quinapril. The Quinapril Heart Failure
Trial Investigators. /. Am. Coll. Cardiol. 1993;22(6):1557-1563.
RADIANCE: Randomized Assessment of Digoxin on Inhibitors
of the ANgiotensin Converting Enzyme.
Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin
from patients with chronic heart failure treated with angiotensin-converting
enzyme inhibitors. RADIANCE Study. N.
Engl. J. Med. 1993;329(l):l-7.
RALES: Randomized Aldactone Evaluation Study.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone
on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. N.
Engl. J. Med. 1999;341(10):709-717.
RESTOR-MV: Randomized Evaluation of a Surgical Treatment
for Off-pump Repair of the Mitral Valve. Trial in progress.
SAVE: Survival and Ventricular Enlargement Trial. Pfeffer
MA, Braumvald E, Moye LA, et al. Effect of captopril on mortality
and morbidity in patients with left ventricular dysfunction
after myocardial infarction. Results of the survival and
ventricular enlargement trial. The SAVE Investigators. N. Engl.
J. Med. 1992;327(10):669-677.
SCD-HeFT: Sudden Cardiac Death in Heart Failure Trial.
Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update
and cumulative meta-analyses from the American CoUege of
Cardiology: WATCH, SCD-HeFT, DİNAMİT, CASINO, INSPI-
RE, STRATUS-US, RIO-Lipids and cardiac resynchronization
therapy in heart failure. Eur. J. Heart Fail. 2004;6(4):501-508.
SHOCK: Should we Emergently Revascularize Occluded Coronaries
for Cardiogenic Shock Trial. Hochman JS, Sleeper LA,
Webb JG, et al. Early revascularization in acute myocardial infarction
complicated by cardiogenic shock. SHOCK Investigators.
Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock. N. Engl. J. Med. 1999;341(9):625-634.
SMILE: Survival of Myocardial infarction Long-Term Evaluation.
Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme
inhibitor zofenopril on mortality and
morbidity after anterior myocardial infarction. The Survival of
Myocardial infarction Long-Term Evaluation (SMILE) Study
Investigators. N. Engl. J. Med. 1995;332(2):80-85.
SOLVD: Studies of Left Ventricular Dysfunction (1997); Am.J.
Cardiol. 79:909-. Dries DL, Domanski MJ, Waclawiw MA,
Gersh BJ. Effect of antithrombotic therapy on risk of sudden
coronary death in patients with congestive heart failure. Am. J.
Cardiol. 1997;79(7):909-913. The SOLVD Investigators. Effect of
enalapril on mortality and the development of heart failure in
asymptomatic patients with reduced left ventricular ejection
fractions. N. Engl. J. Med. 1992;327(10):685-691. Erratum in: N.
Engl. J. Med. 1992;327(24):1768.
SOLVD-T: Studies of Left Ventricular Dysfunction-Treatment
Trial.
The SOLVD Investigators. Effects of enalapril on survival in
patients with reduced left ventricular ejection fractions and
congestive heart failure. N. Engl. J. Med. 1991;325:293-302.
SPAF: Stroke Prevention in Atrial Fibrülation.
The Stroke Prevention in Atrial Fibrülation Investigators. Predictors
of thromboembolism in atrial fibrülation: I. Clinical features
of patients at risk. Ann. Intern. Med. 1992;116(l):l-5. The
Stroke Prevention in Atrial Fibrülation Investigators. Predictors
of thromboembolism in atrial fibrülation: II. Echocardiographic
features of patients at risk. The Stroke Prevention in Atrial
Fibrülation Investigators. Ann. Intern. Med. 1992;116(1):6-
12.
SPORTİF III: Olsson SB. Executive Steering Committee on behalf
of SPORTİF m Investigators. Stroke prevention with the
oral direct thrombin inhibitor ximelagatran compared with
vvarfarin in patients with nonvalvular atrial fibrülation. Lancet
2003;362:1691-1698.
STRETCH: Symptom Tolerability Response to Exercise Trial
of Candesartan CUexitil in Heart Failure Trial.
Riegger GA, Bouzo H, Petr P, et al. Improvement in exercise
tolerance and symptoms of congestive heart failure during treatment
with candesartan cüexetü. Symptom, Tolerability, Response
to Exercise Trial of Candesartan Cüexetü in Heart Failure
(STRETCH) Investigators. Circulation 1999;100(22):2224-2230.
TORIC: TOrasemide in Congestive Heart Failure.
Cosin J, Diez J; TORIC investigators. Torasemide in chronic
heart failure: results of the TORIC study. Eur. J. Heart Fail.
2002;4(4):507-513. Erratum in: Eur. J. Heart Fail 2002;4(5):667.
TRACE: Trandalopril Cardiac Evaluation.
Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of
the angiotensin-converting enzyme inhibitor trandolapril in
patients with left ventricular dysfunction after myocardial
infarction. Trandolapril Cardiac Evaluation (TRACE) Study
Group. N. Engl. ]. Med. 1995;333(25):1670-1676. Torp-Pedersen
C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy
of patients with reduced left-ventricular function after
acute myocardial infarction. TRACE Study Group. Trandolapril
Cardiac Evaluation. Lancet 1999;354(9172):9-12.
UK-HEART: UK Heart Failure Evaulation and Assessment of
Risk Trial.
Nolan J, Batin PD, Andrevvs R, et al. Prospective study of heart
rate variabüity and mortality in chronic heart failure: results of
the UK Heart Failure Evaluation and Assessment of Risk Trial.
G>CM/^’O« 1998;98(15):1510-1516.